Skip to main content
//empty //empty

Unrelenting pain in her hips and weeks of insomnia left Nelly Valbuena desperate for relief from her metastatic breast cancer.

The university professor found freedom from her disease’s cruel side effects in an unexpected remedy: CBD, a compound extracted from the cannabis plant.

Now Valbuena is pushing Ecuador’s government to put into effect recently passed legislation permitting medicinal use of cannabis products so others like her suffering from agonizing illnesses can have new options for pain relief.

Story continues below advertisement

“I desperately needed something to help,” she said. “Only someone living in pain and unable to sleep could know what that means.”

Ecuador’s legislature approved medical use of cannabis containing less than 1 per cent of THC, the high-producing ingredient in marijuana, in September. President Lenín Moreno was given a month to veto but did not. Now Ecuadorians are waiting for the new norm to be published in the official register.

When the law is officially put on the books, Ecuador will be the latest in a tide of Latin American countries approving some form of medicinal cannabis use. Argentina, Colombia, Mexico, Paraguay, Peru and Uruguay have all signed off on permitting therapeutic usage, giving rise to a new industry now growing at a rapid rate and with expanding opportunities.

“In Latin America, with a population of 625 million people, there is great potential,” said Álvaro Torres, a Colombian businessman who co-founded Toronto-based Khiron Life Sciences Corp., which produces and distributes medical cannabis.

Valbuena’s fight against cancer began in 2012 and within four years it had spread to other organs, making her daily life a battle with pain. Valbuena read about cannabis and put a plea on Facebook for help. Within a day, a doctor responded, offering her an oral CBD spray.

“I fell asleep for 16 hours,” she remembered. “It was a huge relief.”

Valbuena and her husband have embarked on a media campaign to chip away at cannabis’ stigma in the socially conservative country.

Story continues below advertisement

CBD is often derived from hemp plants, which look a lot like another type of cannabis, marijuana, but contain only trace amounts of THC. The U.S. government removed industrial hemp from its list of illegal drugs last year.

Though CBD has boomed in popularity, there is very little evidence to back up the health claims the industry touts. Proponents say it treats pain, reduces anxiety and helps with insomnia. But relatively little research has been done on humans to confirm those assertions.

Independent legislator Lourdes Cuesta recalled that before proposing the legislation, lawmakers called in patients and relatives to explain how traditional medicine left them without any quality of life, “but therapeutic cannabis returned it to them.”

Government institutions have not yet commented on how importation and production of medical cannabis will be regulated under the new norms.

Omar Vacas, a scientist at Ecuador’s Catholic University who has studied therapeutic cannabis, said that in the small South American nation it is already possible to find 30 different brands of national and imported medicinal cannabis on the black market.

Once such products are sold legally in pharmacies, there could potentially be a million consumers, he said.

Story continues below advertisement

Oscar Farith Pino Herrera, founder of a non-profit group promoting industrial hemp, added that Ecuador has ideal climatic conditions for growing hemp plants, which he said have a wide variety of potential uses beyond treating medical ailments.

“It could also help in the generation of jobs,” he said.

Alexis Ponce, Valbuena’s husband, said his family takes comfort in knowing that their own battles will one day help others.

“The relatives of someone with cancer or pain suffer just as much as the patient,” he said.

Follow related topics

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies